Document: Venofundin solution for infusion ENG SmPC change

• Venofundin solution for infusion SmPC
• Venofundin solution for infusion ENG SmPC

---

Summary of Product Characteristics

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions.

Venofundin 60 mg/ml solution for infusion

1000 ml of solution contain:

Hydroxyethyl starch (HES) 60.0 g

(Molar substitution: 0.42)

(Average molecular weight: 130,000 Da)

Sodium chloride 9.0 g

Electrolyte concentrations:

Sodium 154 mmol/l

Chloride 154 mmol/l

For the full list of excipients, see section 6.1

Solution for infusion.

Clear, colourless aqueous solution.

pH: 4.06.5

Theoretical osmolarity: 309 mOsmol/l

Acidity (titration to pH 7.4): <1.0 mmol/l

Treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. (see sections 4.2, 4.3 and 4.4)

Posology

Use of Hydroxyethyl starch should be restricted to the initial phase of volume resuscitation with a maximum time interval of 24 h.

The daily volume and the infusion rate depend on the amount of blood lost and how much fluid is required to restore haemodynamicparameters.

The first 10–20 ml should be infused slowly and undercareful monitoring of the patient so that anyanaphylactic / anaphylactoid reaction can be detected as early as possible.

The volume limitations given by the degree of haemodilution should be observed, see sections 4.4 and 4.8.

Adults

Maximum daily volume:

The maximum daily dose is 30 ml/kg body weight (BW) (equivalent to 1.8 g of Hydroxyethyl starch per kg BW). This is equivalent to 2 100ml of Venofundin 60 mg/ml for a patient weighing 70 kg.

Maximum infusion rate:

The maximum infusion rate depends on the clinical situation. Patients in acute shock can be given up to 20 ml per kg of body weight per hour (equivalent to 0.33 ml per kg BW per min or 1.2 g of Hydroxyethyl starch per kg BW per hour).

In life-threatening situations, 500 ml may be administered by manual pressure infusion. See section 4.2‘Method of administration’.

The lowest possible effective dose should be applied. Treatment should be guided by continuous haemodynamic monitoring so that the infusion is stopped as soon as appropriate haemodynamic goals have been achieved. The maximum recommended daily dose must not be exceeded.

Elderly patients

See section 4.4.

Paediatric population:

Data are limited in children therefore it is recommended not to use Hydroxyethyl starch products in this population.

Method of administration

Intravenous use.

In the case of a rapid infusion under pressure, using plastic container with air space inside, the container and infusion set should be emptier of air before the infusion is started. This is to avoid the risk of air embolism that might otherwise be associated with the infusion.

• hypersensitivity to the active substances or to any of the other excipients listed in section 6.1

• sepsis

• burns

• renal impairment or renal replacement therapy

• intracranial or cerebral haemorrhage

• critically ill patients (typically admitted to the intensive care unit)

• hyperhydration

• pulmonary oedema

• dehydration

• severe hypernatraemia or severe hyperchloraemia

• severely impaired hepatic function

• congestive heart failure

• severe coagulopathy

• organ transplant patients

Because of the risk of allergic (anaphylactic / anaphylactoid) reactions, the patient should be monitored closely and the infusion instituted at a low rate (See section 4.8).

The indication for volume replacement with Hydroxyethyl starch has to be considered carefully, and haemodynamic monitoring is required for volume and dose control. (See also section 4.2.)

Sufficient fluid intake must be ensured.

Volume overload due to overdose or too rapid infusion must always be avoided. The dosage must be adjustedcarefully, particularly in patients with pulmonary or cardiocirculatory problems. Serum electrolytes, fluid balance and renal function should be monitored closely. Electrolytes and fluids should be substituted according to individual requirements.

Hydroxyethyl starch products are contraindicated in patients with renal impairment or renal replacement therapy (see section 4.3). The use of Hydroxyethyl starch must be discontinued at the first sign of renal injury. An increased need for renal replacement therapy has been reported up to 90 days after Hydroxyethyl starch administration. Monitoring of renal function in patients is recommended for at least 90 days.

Particular caution should be exercised when treating patients with impaired hepatic function or in patients with blood coagulation disorders.

Severe haemodilution resulting from high doses of Hydroxyethyl starch solutions must also be avoided in the treatment of hypovolaemic patients.

In the case of repeated administration, blood coagulation parameters should be monitored carefully. Discontinue the use of Hydroxyethyl starch at the first sign of coagulopathy.

In patients undergoing open heart surgery in association with cardiopulmonary bypass the use of Hydroxyethyl starch products is not recommended due to the risk of excess bleeding.

Elderly patients

Elderly patients, who are more likely to suffer from cardiac insufficiency and renal impairment,should be closelymonitored during treatment, and the dosage should be carefully adjusted, in order to avoid cardiocirculatory and renal complications resulting from hypervolaemia.

Surgery and trauma:

There is a lack of robust long term safety data in patients undergoing surgical procedures and in patients with trauma. The expected benefit of treatment should be carefully weighed against uncertainty with regard to this long term safety. Other available treatment options should be considered.

Paediatric population:

Data are limited in children therefore it is recommended not to use Hydroxyethyl starch products in this population. (see section 4.2)

Influence on laboratory tests

Transientlyraised alpha-amylase levels can occur after administration of solutions with Hydroxyethyl starch.

This should not be interpretedas evidenceofpancreatic disorder (see section 4.8).

Aminoglycosides

The adverse effects of aminoglycosides on kidneys may be increased in combination with Hydroxyethyl starch infusions.

Medicinal products causing sodium retention

Consideration should be given to the concomitant administration of medicinal products that can cause sodium retention.

Pregnancy

There are no or limited amount of data from the use of Hydroxyethyl starch in pregnant women. Animal reproduction toxicity studies with similar products have revealed vaginal bleeding, embryotoxicity and teratogenicity after repeated treatment in test animals (see section 5.3).

Harmful effects on the foetus can occur with Hydroxyethyl starch related anaphylactic/anaphylactoid reactions in treated pregnant women.

Venofundin should be used during pregnancy only if the potential benefits outweigh the possible risk to the foetus. This should be borne in mind in particular if treatment with Venofundin is being considered during the first trimester.

Special care must be taken to avoid overdose resulting in hypervolaemia with consecutive pathological haemodilution and foetal hypoxia (see section 5.3).

Breast-feeding

It is not known whether Hydroxyethyl starch passes into breast milk, caution should be exercised on administration to lactating women. The temporary cessation of breast-feeding may be considered.

Fertility

No data available.

This medicinal product has no influence on the ability to drive and use machines.

General

The most common side effects observed (very common, 1/10) are directly related to the therapeutic effects of starch solutions and the volume given, i.e., dilution of the blood as a result of the filling of the intravascular space without administering blood components at the same time. Coagulation factor dilution can also occur. Serious anaphylactic/anaphylactoid reactions have been reported and may require immediate action (please refer also to the section “Anaphylactic/Anaphylactoid reactions” below)

Anaphylactic / Anaphylactoid reactions

After administration of Hydroxyethyl starch, anaphylactic / anaphylactoid reactions of various degrees can occur which are not dose-dependent.. Therefore, all patients receiving starch infusion should be monitored closely for anaphylactic / anaphylactoid reactions. In the event of an anaphylactic / anaphylactoid reaction, the infusion should be discontinued immediately and the usual acute treatment given.

It is not possible to predict by tests which patients may be expected to suffer an anaphylactic / anaphylactoid reaction nor is it possible to predict the course and severity of such a reaction.

Prophylaxis with corticosteroids has not been shown to have a preventive effect.

Reporting of suspected adverse reactions

Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in

[To be completed nationally.]

Symptoms

Overdose with Venofundin leads to unintended hypervolaemia and circulatory overload with a significant fall in haematocrit and plasma proteins. This may be associated with consecutive impairment of heart and lung function (pulmonary oedema).

Treatment

In this case, the infusion must be stopped immediately, and administration of diuretics be considered. If an overdose occurs, the patient should be treated symptomatically and electrolytes should be monitored.

Pharmacotherapeutic group: Blood substitute and plasma proteins,

ATC code: B05A A07

Mechanism of action

Venofundin 60 mg/ml is a colloidal plasma volume substitute containing 6% Hydroxyethyl starch in 0.9 per cent sodium chloride solution. Its average molecular weight is 130,000 Dalton and its molar substitution is 0.42.

It is iso-oncotic, i.e., the increase in the intravascular plasma volume is equivalent to the infused volume.

With isovolaemic administration, the volume expanding effect persists for at least 4-9 hours. The duration of the volume effect depends primarily on molar substitution and to a lesser extent on the mean molecular weight. Intravascular hydrolysis of Hydroxyethyl starch polymers results in the continuous release of smaller molecules which are also oncotically active before being excreted via the kidneys.

Venofundin 60 mg/ml may reduce haematocrit and the plasma viscosity.

Venofundin also has a favourable effect on the microcirculation by altering the flow characteristics of the blood.

General

The characteristics of the electrolytes contained in Venofundin are the same as in normal physiology.

Absorption

As Venofundin is administered intravenously, the bioavailability is 100%.

Distribution

Hydroxyethyl starch is a mixture of several molecules with different degree of substitution and molecular weight. Like all colloids, Hydroxyethyl starch, too, is temporarily stored particularly in the cells of the mononuclear phagocyte system (MPS), however, without producing any irreversible toxic effects on liver, lungs, spleen and lymph nodes. Minor quantities of the stored active substance in the skin are still histologically detectable several months after administration. Such storage phenomena are assumed to be the cause for the itching that has been observed after long-term administration of high doses of Hydroxyethyl starch.

Hydroxyethyl starch does not pass the blood-brain barrier. No relevant foetal Hydroxyethyl starch concentration was detectable in the blood of the umbilical cord excluding the possibility of a maternal-foetal-transfer of Hydroxyethyl starch.

Biotransformation/Elimination

Elimination is dependent on the degree of substitution and to a lesser extent on molecular weight. Molecules which in terms of size are below the so-called renal threshold are excreted byglomerular filtration. Larger molecules are first degraded by alpha-amylase before they are excreted renally. The rate at which the molecules are degraded decreases with increasingdegree of substitution of the molecules.

After a single infusion of 1000 ml Venofundin 60 mg/ml, plasma clearance is 19 ml/min and AUC 58 mg×h×ml–1. The terminal serum half-life is about 4-5hours.

Pharmacokinetics in paediatric populations

No pharmacokinetic data from the use in children are available.

No toxicology animal studies have been conducted with Venofundin 60 mg/ml. Published animal toxicology studies with repeated hypervolemic treatment with similar Hydroxyethyl starch products have revealed bleeding and extensive histiocytosis (accumulation of foam –like histiocytes/macrophages) in several organs with an increase in weight of the liver, kidney, and spleen. Infiltration of fat and vacuolation of organs as well as elevations of plasma AST and ALT have been reported. It has been suggested that some of the effects described were caused by haemodilution, increased circulatory load and uptake and accumulation of starch in phagocytic cells.

Similar Hydroxyethyl starch products have been reported to be non-genotoxic in standard tests.

Reproduction toxicology studies with Hydroxyethyl starch products have shown vaginal bleeding and signs of embryo-/foetotoxicity and teratogenicity associated with repeated administration to test animals.

These effects may be due to haemodilution and result in foetal hypoxia, and hypervolemia.

Bleeding can also be in part a direct consequence of the effects that Hydroxyethyl starch has on blood coagulation.

Water for Injections

In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.

Unopened

Polyethylene bottle (Ecoflac plus): 3 years

Plastic bag (Ecobag): 2 years

Shelf life after first opening:

The product should be administered immediately after connecting the container to the administration set.

Do not freeze.

Venofundin is available in the following containers and pack sizes:

10 x 500 ml

20 x 250 ml

20 x 500 ml

Not all pack sizes may be marketed.

No special requirements for disposal.

Administration should begin immediately after connecting the container to the administration set.

For single use only.

Use as soon as the primary packaging is opened. Any unused contents should be discarded.

Do not re-connect partially used containers.

Use only if the solution is clear, colourless and the container is undamaged.

B. Braun Melsungen AG

Carl-Braun-Strasse 1

34212 Melsungen

Germany

Postal address

B. Braun Melsungen AG

34209 Melsungen, Germany

Telephone: +49 5661 71 0

Telefax: +49 5661 71 4567

[To be completed nationally.]

[To be completed nationally.]

10 date of revision of the text

28 February 2014